These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 30885693)

  • 21. Participant experiences using novel home-based blood collection device for viral load testing in HIV cure trials with analytical treatment interruptions.
    Dubé K; Agarwal H; Carter WB; Dee L; Taylor J; Roebuck C; Peterson B; Patel H; Ndukwe S; Lynn KM; Lalley-Chareczko L; Hiserodt E; Kim S; Rosenbloom D; Evans BR; Anderson M; Hazuda DJ; Bateman K; Howell BJ; Azzoni L; Mounzer K; Tebas P; Montaner LJ
    HIV Res Clin Pract; 2022 Aug; 23(1):76-90. PubMed ID: 35968737
    [No Abstract]   [Full Text] [Related]  

  • 22. Analytical treatment interruption in children living with HIV: position statement from the EPIICAL consortium.
    Kuhn L; Barnabas S; Cotugno N; Peay H; Goulder P; Cotton M; Violari A; Pahwa S; Reddy K; Tagarro A; Otwombe K; Fry S; Vaz P; Lain MG; Nhampossa T; Archary M; Maiga AI; Puthanakit T; Kityo CM; Foster C; Rojo P; Klein N; Nastouli E; Tiemessen CT; de Rossi A; Ndung'u T; Persaud D; Lichterfeld M; Giaquinto C; Palma P; Rossi P;
    Lancet HIV; 2024 Oct; 11(10):e700-e710. PubMed ID: 39059402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study).
    Castagna A; Muccini C; Galli L; Bigoloni A; Poli A; Spagnuolo V; Nozza S; Racca S; Galli A; Cinque P; Carini E; Lazzarin A
    J Antimicrob Chemother; 2019 Jul; 74(7):2039-2046. PubMed ID: 31225610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Attitudes About Analytic Treatment Interruption (ATI) in HIV Remission Trials with Different Antiretroviral Therapy (ART) Resumption Criteria.
    Peay HL; Rennie S; Cadigan RJ; Gwaltney A; Jupimai T; Phanuphak N; Kroon E; Colby DJ; Ormsby N; Isaacson SC; Vasan S; Sacdalan C; Prueksakaew P; Benjapornpong K; Ananworanich J; Henderson GE
    AIDS Behav; 2022 May; 26(5):1504-1516. PubMed ID: 34997386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical trials of antiretroviral treatment interruption in HIV-infected individuals.
    Lau JSY; Smith MZ; Lewin SR; McMahon JH
    AIDS; 2019 Apr; 33(5):773-791. PubMed ID: 30883388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lessons learned from HIV antiretroviral treatment interruption trials.
    Wen Y; Bar KJ; Li JZ
    Curr Opin HIV AIDS; 2018 Sep; 13(5):416-421. PubMed ID: 29878912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions.
    Graziani GM; Angel JB
    J Int AIDS Soc; 2015; 18(1):20497. PubMed ID: 26561337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute HIV-1 infection viremia associate with rebound upon treatment interruption.
    Mdluli T; Li Y; Pinyakorn S; Reeves DB; Cardozo-Ojeda EF; Yates A; Intasan J; Tipsuk S; Phanuphak N; Sacdalan C; Colby DJ; Kroon E; Crowell TA; Thomas R; Robb ML; Ananworanich J; de Souza M; Phanuphak P; Stieh DJ; Tomaka FL; Trautmann L; Ake JA; Hsu DC; Francisco LV; Vasan S; Rolland M
    Med; 2022 Sep; 3(9):622-635.e3. PubMed ID: 35870446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early antiretroviral therapy in HIV-infected infants: can it lead to HIV remission?
    Shiau S; Abrams EJ; Arpadi SM; Kuhn L
    Lancet HIV; 2018 May; 5(5):e250-e258. PubMed ID: 29739699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ready for HIV Dual Therapy? - New Data from International HIV/AIDS Society 2017.
    Yendewa GA; Salata RA
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint.
    Giron LB; Papasavvas E; Azzoni L; Yin X; Anzurez A; Damra M; Mounzer K; Kostman JR; Sanne I; Firnhaber CS; Tateno H; Liu Q; Montaner LJ; Abdel-Mohsen M
    AIDS; 2020 Apr; 34(5):681-686. PubMed ID: 31972605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ethical and practical considerations for mitigating risks to sexual partners during analytical treatment interruptions in HIV cure-related research.
    Dubé K; Kanazawa J; Dee L; Taylor J; Campbell DM; Brown B; Johnson MO; Saberi P; Sauceda JA; Sugarman J; Peluso MJ
    HIV Res Clin Pract; 2021 Feb; 22(1):14-30. PubMed ID: 33757411
    [No Abstract]   [Full Text] [Related]  

  • 33. Impact of Treatment Interruption on HIV Reservoirs and Lymphocyte Subsets in Individuals Who Initiated Antiretroviral Therapy During the Early Phase of Infection.
    Huiting ED; Gittens K; Justement JS; Shi V; Blazkova J; Benko E; Kovacs C; Wender PA; Moir S; Sneller MC; Fauci AS; Chun TW
    J Infect Dis; 2019 Jun; 220(2):270-274. PubMed ID: 30840763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Considerations for Increasing Racial, Ethnic, Gender, and Sexual Diversity in HIV Cure-Related Research with Analytical Treatment Interruptions: A Qualitative Inquiry.
    Dubé K; Kanazawa J; Campbell C; Boone CA; Maragh-Bass AC; Campbell DM; Agosto-Rosario M; Stockman JK; Diallo DD; Poteat T; Johnson M; Saberi P; Sauceda JA
    AIDS Res Hum Retroviruses; 2022 Jan; 38(1):50-63. PubMed ID: 33947268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Essential Need for Trust When Transmission Risk Cannot Be Eliminated in HIV-Remission Trials.
    Rennie S; Henderson G; Phanuphak N; Kuczynski K; Colby D; Ormsby N; Kroon E; Hsu D; Likhitwonnawut U; Vasan S; Sacdalan C; Jupimai T; Butterworth O; Peay H
    Ethics Hum Res; 2023; 45(4):2-15. PubMed ID: 37368521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virologic and Immunologic Features of Simian Immunodeficiency Virus Control Post-ART Interruption in Rhesus Macaques.
    Strongin Z; Micci L; Fromentin R; Harper J; McBrien J; Ryan E; Shenvi N; Easley K; Chomont N; Silvestri G; Paiardini M
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32350073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Duration of Antiretroviral Therapy Adherence Interruption Is Associated With Risk of Virologic Rebound as Determined by Real-Time Adherence Monitoring in Rural Uganda.
    Haberer JE; Musinguzi N; Boum Y; Siedner MJ; Mocello AR; Hunt PW; Martin JN; Bangsberg DR
    J Acquir Immune Defic Syndr; 2015 Dec; 70(4):386-92. PubMed ID: 26110445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control.
    Assoumou L; Weiss L; Piketty C; Burgard M; Melard A; Girard PM; Rouzioux C; Costagliola D;
    AIDS; 2015 Sep; 29(15):2003-7. PubMed ID: 26355572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell-Associated HIV-1 Unspliced-to-Multiply-Spliced RNA Ratio at 12 Weeks of ART Predicts Immune Reconstitution on Therapy.
    Scherpenisse M; Kootstra NA; Bakker M; Berkhout B; Pasternak AO
    mBio; 2021 Mar; 12(2):. PubMed ID: 33688002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.
    Bailón L; Llano A; Cedeño S; Escribà T; Rosás-Umbert M; Parera M; Casadellà M; Lopez M; Pérez F; Oriol-Tordera B; Ruiz-Riol M; Coll J; Perez F; Rivero À; Leselbaum AR; McGowan I; Sengupta D; Wee EG; Hanke T; Paredes R; Alarcón-Soto Y; Clotet B; Noguera-Julian M; Brander C; Molto J; Mothe B;
    Nat Med; 2022 Dec; 28(12):2611-2621. PubMed ID: 36302893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.